[Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone].
A complex of neuroprotective therapy, including a new Russian neuropeptide semax, was used in the treatment of glaucoma patients with normalized ophthalmic tone. Electrophysiological and computer methods of examination demonstrated the advantages of new therapy over traditional neuroprotective treatment for glaucoma. The efficiency is due to pathogenetic activity of semax possessing both neuroprotective and neurotrophic effects.
Kurysheva
N I
NI
Shpak
A A
AA
Ioĭleva
E E
EE
Galanter
L I
LI
Nagornova
N D
ND
Shubina
N Iu
NIu
Shlyshalova
N N
NN
D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000368:Aged; D005260:Female; D005901:Glaucoma / Q000150:complications*; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009901:Optic Nerve Diseases / Q000188:drug therapy*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D058609:Visual Field Tests
D018696:Neuroprotective Agents; D010446:Peptide Fragments; C048487:ACTH (4-7), Pro-Gly-Pro-; D000324:Adrenocorticotropic Hormone